



The General Manager,
Pakistan Stock Exchange Limited
Stock Exchange Building,
Stock Exchange Road,
Karachi.

29 July, 2025

Subject:

Disclosure of Material Information

Dear Sir,

In accordance to the section 96 and 131 of the Securities Act 2015 and Clause 5.6.1(a) of the Rule Book of the Pakistan Stock Exchange Limited, Highnoon Laboratories Limited ("The Company") hereby conveys the following information:

"The Company has entered into a strategic partnership with **Beximco Pharmaceuticals Limited**, a leading Bangladesh based pharmaceutical company having state-of-the-art manufacturing facilities, accredited by the regulatory authorities of USA, Australia, European Union, Canada, and Brazil.

An MoU has been signed between the Company and Beximco Pharmaceuticals Limited to collaborate for the distribution and marketing of specialized pharmaceutical products in Pakistan, with the focus on high-burden therapeutic areas including respiratory, diabetes, and cardiovascular diseases. Through this partnership the Company will bring newer therapies, dosage forms and delivery systems for the ease of use and better clinical results for patients and improving access to the advanced medications.

This strategic alliance will make a significant contribution to the recent expansion of trade relations and economic cooperation between Pakistan and Bangladesh."

A disclosure form is attached herewith (Annexure "A"). You may please inform the members of your Exchange, accordingly.

Bagar Hasan

Senior General Counsel & Company Secretary

Encl: as above

Copy to:

Executive Director,
Supervision Department,
Supervision Division,
SECP, Islamabd.





HIGHNOON LABORATORIES LIMITED DISCLOSURE FORM IN TERMS OF SECTION 96 AND 131 OF THE SECURITIES ACT 2015

29 July, 2025

Name of the Company	Highnoon Laboratories Limited
Date of Report (Date of earliest event reported if applicable)	N/A
Exact Name of the Company as specified in its Memorandum	Highnoon Laboratories Limited
Registered address of the Company	17.5 KM Multan Road, Lahore.
Contact Information	Baqar Hasan Senior General Counsel & Company Secretary Tel: +924236407346 Fax: +924237510037
Disclosure of inside information by the Company in terms of Securities Act, 2015	The Company has entered into a strategic partnership with Beximco Pharmaceuticals Limited, a leading Bangladesh based pharmaceutical company having state-of-the-art manufacturing facilities, accredited by the regulatory authorities of USA, Australia, European Union, Canada, and Brazil.
	An MoU has been signed between the Company and Beximco Pharmaceuticals Limited to collaborate for the distribution and marketing of specialized pharmaceutical products in Pakistan, with the focus on high-burden therapeutic areas including respiratory, diabetes, and cardiovascular diseases. Through this partnership the Company will bring newer therapies, dosage forms and delivery systems for the ease of use and better clinical results for patients and improving access to the advanced medications.
	This strategic alliance will make a significant contribution to the recent expansion of trade relations and economic cooperation between Pakistan and Bangladesh.

Baqar Hasan

Senior General Counsel & Company Secretary